Immunic Inc. (IMUX) Announces Proposed Common Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- Wall Street ends choppy session lower as tech shares drop
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil prices fall 1% to 4-month lows as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
Immunic, Inc. Announces Proposed Public Offering of Common Stock
June 9, 2020 7:39 PM EDTNEW YORK, June 9, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced it has commenced a public offering of shares of its common stock.
Immunic intends to use the proceeds from the offering to fund the ongoing clinical development of the Company's three small molecule products: IMU-838, IMU-935 and IMU-856, and for other general corporate purposes, including to investigate IMU-838, the Company's lead asset, as a potential oral treatment... More
